Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)Yongge Liu, Jeffrey Hafkin, Makoto Matsumoto et al.|Tuberculosis|2018Cited by 164
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosisMamoru Fujiwara, Makoto Matsumoto, Masanori Kawasaki et al.|Tuberculosis|2017Cited by 163
MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical ConcentrationKelly Wallace Stinson, Lawrence Geiter, Natalia Kurepina et al.|Antimicrobial Agents and Chemotherapy|2016Cited by 57
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant TuberculosisSuresh Mallikaarjun, Yongge Liu, Moti Chapagain et al.|Antimicrobial Agents and Chemotherapy|2020Cited by 24
Corrigendum to “Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis” [Tuberculosis 108 (January 2018) 186–194]Mamoru Fujiwara, Makoto Matsumoto, Masanori Kawasaki et al.|Tuberculosis|2018Cited by 3